CHEK1 and prostate carcinoma: Enhanced activation of Chk1 led to resistance to chemotherapy or radiotherapy, as well as to other anticancer therapies, in multiple types of cancer cells, including stem cells from brain glioblastoma, prostate cancer, and non-small-cell lung cancer [26].